Amp 2019 Table of Contents
Total Page:16
File Type:pdf, Size:1020Kb
November 7-9, 2019 Baltimore Convention Center Baltimore, MD, USA AMP_OnsiteProgram_Covers.indd 1 10/18/19 9:39 AM PICKING UP PIK3CA WE SEE THE FUTURE OF GENOMIC MUTATIONS DIAGNOSTICS CLEARLY. Learn about the most common mutation in HR+/HER2- advanced breast cancer (aBC) 1-4 and how to detect it at BOOTH 2741 Personal Genome Diagnostics (PGDx) is Empowering the Fight Against Cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and health economics by developing an INNOVATION SPOTLIGHT innovative portfolio of regulated with Jean Lopategui, MD Associate Professor of Pathology tissue-based and non-invasive liquid Director of Translational Genomics Program Director of Molecular Genetic biopsy genomic based Next Pathology Fellowship Generation Sequencing (NGS) Cedars-Sinai Medical Center Los Angeles, California products for laboratories worldwide. Friday, November 8, 2019 We are placing the power of proximity 10:00 AM - 10:30 AM in the hands of physicians and lab at STAGE 2 directors, and putting the power of control back into your patient care Join us as Dr Jean Lopategui discusses PIK3CA mutations in ecosystem. HR+/HER2- aBC and how to detect them. References: 1. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. 2. Tolaney S, Toi M, Neven P, et al. Presented at: DRIVEN BY SCIENCE. 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; INSPIRED BY PATIENTS. Atlanta, GA. 3. Di Leo A, Johnston S, Seok Lee K, et al. Lancet Oncol. 2018;19(1):87-100. 4. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730. EMPOWERING PHYSICIANS. COMMITTED TO YOU. Novartis Pharmaceuticals Corporation Want to learn more about our products and partnerships, East Hanover, New Jersey 07936-1080 © 2019 Novartis 10/19 BST-1222219 visit pgdx.com or call (443) 602-8833. AMP_OnsiteProgram_Covers.indd 2 10/18/19 9:39 AM APUS19DDBH2885_M4_AMP_Print_Journal_Ad_BkCVR_PP.indd 1 10/10/19 10:13 PM AMP 2019 TABLE OF CONTENTS General Information Welcome from the AMP Program Chair 2 Code of Conduct 7 Maps 9 Highlights & General Information 12 Award for Excellence 2019 Recipient 22 Jeffrey A. Kant Leadership Award 2019 Recipient 23 Meritorious Service Award 2019 Recipient 24 2019 Travel Award Recipients 25 Board, Committee, Working Group Rosters 2019 26 Continuing Education Continuing Education Information 41 Program At-A-Glance Meeting-at-a-Glance Chart 47 Meeting-at-a-Glance Listing 48 Thursday Program Thursday Session Descriptions 71 Friday Program Friday Session Descriptions 83 Saturday Program Saturday Session Descriptions 95 Speaker Information Invited Speaker Bios 109 Posters Poster Information 139 Poster Listing 140 Author Index 166 Expo Explore the Expo Hall 187 Expo Hours & Dates 188 Innovation Spotlight Stage Schedule 189 Floorplan 193 Exhibitor Listing 194 Exhibitor Descriptions 196 AMP_OnsiteProgram_v15.indd 1 10/18/19 3:40 PM ANNUAL MEETING & EXPO ANNUAL MEETING & EXPO WELCOME TO THE 2019 Association for Molecular Pathology Annual Meeting & Expo! It has been a true pleasure to work alongside the members of the 2019 AMP Annual Meeting Program Committee in putting together this program, marking the 25th Anniversary of our organization. In designing the program for this Silver Anniversary, we were challenged to acknowledge the history of our organization and our specialty, while also reporting on the present, and projecting into the future. Our program is an attempt to concurrently respect our historical traditions and, also, to establish some new ones. I'm very proud of the work that your committee conducted, and of the program that we compiled. Among the new features we are bringing to the meeting this year are the engagement of meetings with guest societies, Infectious Diseases Society of America (IDSA) and (American College of Medical Genetics and Genomics (ACMG). These organizations are made up of health care specialists, in infectious diseases and human genetics, respectively, whose work has substantial overlap with the work conducted by AMP. This year, each of these organizations will be hosting a 2.5 hour symposia prior to our meeting, these symposia will present issues in their specialties that are shared with ours, and to help foster inter- organizational and cross-specialty relations and cooperation. I offer a hearty welcome to the members of IDSA and ACMG who are joining us this year, and hope that this is a tradition that continues, and expands, in the future. Another feature that we are bringing to the meeting this year is to engage with AMP committees, to develop sessions of mutual interest to the attendees. Historically, the program has been largely developed through the work of the subdivision representatives - two each from genetics, infectious diseases, informatics, hematopathology, solid tumors, and technical topics. This year, we also engaged with the cross-practice committees to develop sessions. These have brought us several exciting new features such as the Pipeline Showcase, the Business of Molecular Lab Management, the International Quality Assurance Program, and the Future Practice of Molecular Pathology. We have redesigned some of the meeting formats, with an emphasis on active learning in the workshop sessions, refocusing the "early bird" sessions as targeted talks on specific individual topics, enabled more, and later, late breaking abstracts (case studies) from our trainees, and implemented short educational courses to take place during the days leading up to the main meeting. 2 | 25th ANNIVERSARY CELEBRATION AMP_OnsiteProgram_v15.indd 2 10/18/19 3:40 PM ANNUAL MEETING & EXPO ANNUAL MEETING & EXPO However, while these and other aspects of the meeting are new, much will remain familiar. We will, again, have a full day of corporate workshops from our vendors during the day before the meeting. We will, again, be taking a trip to Capitol Hill to meet and talk with members of Congress about public health issues of interest to our specialty, we will, again, learn about practice guidelines in development, we will again learn about exciting new findings at posters and platforms, and we will, again, have hours and hours of fascinating talks from leaders in our field, both from within the organization and from invited experts from other fields. As always, our meeting kicks off in earnest with the Award for Excellence in Molecular Diagnostics Presentation and Lecture. This year's honoree is Dr. Russ Higuchi, a true pioneer in our field, whose many accomplishments date back to (and precede) the origins of the polymerase chain reaction, and include developing the first protocols for the use of PCR in forensic and ancient genetics investigations, for cloning from cDNA, and the invention of real-time PCR with closed tube fluorescence detection, as well as many other innovative uses of DNA as a diagnostic analyte, most recently for improved rapid non-invasive detection of bladder cancers. I am really excited about this year's meeting, which was the culmination of a tremendous amount of work spanning over a year, that was conducted by a dedicated and talented team of individuals, who have worked hard for very little recognition. I thank the members of our planning committee, Esther Babady, Jennifer Dien-Bard, Raj Emmadi, Mark Ewalt, Rashmi Kanagal, Peter Kang, Matt Lebo, Tina Lockwood, Angshumoy Roy, Fernanda Sabato, Elaine Spector, Renee Webb, and next year's Program Chair, Jane Gibson. Beyond the faculty volunteers, however, we all thank the AMP staff who are the backbone of the entire organization and who absolutely make this (and all our crazy ideas) happen; if you see them around the meeting, please join me, and extend your own thanks to Lucia Barker, Tara Burke, Elisabeth Campbell, Kathleen Carmody, Eriko Clements, Sara Hamilton, Rhonda Jenkins, Jon Korman, Laurie Menser, Andy Noble, Mrudula Pullambhatla, Crystal Quinones, TaNika Switzer, Robyn Temple-Smolkin, Sarah Thibault-Sennett, Michele Zink, and our Executive Director, Mary Williams From the 2019 Program Committee, Neal I. Lindeman, MD 2019 Program Committee Chair 25th ANNIVERSARY CELEBRATION | 3 AMP_OnsiteProgram_v15.indd 3 10/18/19 3:40 PM ANNUALGENERAL MEETING INFORMATION & EXPO GENERAL INFORMATION NOTES 4 | 25th ANNIVERSARY CELEBRATION AMP_OnsiteProgram_v15.indd 4 10/18/19 3:40 PM THE LATEST INFORMATION ABOUT BIOMARKER TESTING ARE YOU INFORMATION GENERAL UP TO DATE? VISIT BOOTH 2925 TO LEARN MORE The sponsor of this ad verifies that they had no input into decision making regarding the selection of educational programs, content, or faculty for this 2019 Annual Meeting. Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. US-LAM-00350 07/19 AMP_OnsiteProgram_AdTabs.indd 1 10/18/19 9:38 AM PICKING UP PIK3CA MUTATIONS EUROPE Learn about the most common mutation in HR+/HER2- advanced breast cancer (aBC) and how to detect it at BOOTH 27411-4 2020 Clinical Genomics: Beyond the Somatic Mutation INNOVATION SPOTLIGHT with Jean Lopategui, MD Associate Professor of Pathology Director of Translational Genomics Program Director of Molecular Genetic Pathology Fellowship Cedars-Sinai Medical Center Los Angeles, California Friday, November 8, 2019 GENERAL INFORMATION GENERAL 10:00 AM - 10:30 AM at STAGE 2 Join us as Dr Jean Lopategui discusses PIK3CA mutations in HR+/HER2- aBC and how to detect them. References: 1. The Cancer Genome Atlas Network. Comprehensive